BRNS
Barinthus Biotherapeutics PLC - ADR

166
Loading...
Loading...
News
all
press releases
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barclays analyst Carter Gould maintained a Buy rating on Barinthus Biotherapeutics (BRNS Research Report) today and set a price target of $3.00...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were...
Benzinga·1y ago
News Placeholder
Barinthus Biotherapeutics (NASDAQ:BRNS) PT Lowered to $8.00 at HC Wainwright
Barinthus Biotherapeutics (NASDAQ:BRNS Free Report) had its price objective cut by HC Wainwright from $15.00 to $8.00 in a research report released on Thursday, Benzinga reports. They...
Ticker Report·1y ago
News Placeholder
Barinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023
Despite Revenue Decline, R&D Advances Signal Strong Future PotentialRelated Stocks: BRNS...
GuruFocus·1y ago
News Placeholder
Wall Street Analysts Are Bullish on Top Healthcare Picks
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Context Therapeutics (CNTX Research Report) and Barinthus Biotherapeutics...
TipRanks Financial Blog·1y ago
News Placeholder
Barinthus Biotherapeutics: Q4 Earnings Insights
read more...
Benzinga·1y ago
News Placeholder
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31...
Globe Newswire·1y ago
News Placeholder
Barinthus Biotherapeutics (BRNS, $3.04) RSI Indicator left the oversold zone on January 24, 2024
This is a signal that BRNS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·2y ago
News Placeholder
Barinthus Biotherapeutics (BRNS, $3.03) RSI Indicator left the oversold zone on January 23, 2024
This is a signal that BRNS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·2y ago
News Placeholder
Barinthus Biotherapeutics (BRNS, $3.05) RSI Indicator left the oversold zone on January 22, 2024
This is a signal that BRNS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·2y ago

Latest BRNS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.